A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma

ABSTRACT Tailored treatment for patients with rectal cancer requires clinically available markers to predict their response to neoadjuvant treatment. The quantity of tumor-infiltrating lymphocytes (TILs) in pre-operative tumor biopsies has been suggested to predict a favorable response, but opposing results exist. A biopsy-adapted Immunoscore (ISB) based on TILs has recently emerged as a promising predictor of tumor regression and prognosis in (colo)rectal cancer. We aimed to refine the ISB for prediction of response using multiplex immunofluorescence (mIF) on pre-operative rectal cancer biopsies. We combined the distribution and density of conventional T cell subsets and γδT cells with a type I Interferon (IFN)-driven response assessed using Myxovirus resistance protein A (MxA) expression. We found that pathological complete response (pCR) following neoadjuvant treatment was associated with type I IFN. Stratification of patients according to the density of CD8+ in the entire tumor tissue and MxA+ cells in tumor stroma, where equal weight was assigned to both parameters, resulted in improved predictive quality compared to the ISB. This novel stratification approach using these two independent parameters in pre-operative biopsies could potentially aid in identifying patients with a good chance of achieving a pCR following neoadjuvant treatment.

[1]  U. Yrlid,et al.  A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells , 2022, Cancers.

[2]  Zaiyi Liu,et al.  Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density , 2021, Journal of inflammation research.

[3]  Qingling Zhang,et al.  Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer , 2021, Frontiers in Oncology.

[4]  Jian Zhang,et al.  The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting , 2021, Frontiers in Immunology.

[5]  T. Sjöblom,et al.  A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer , 2020, Cancers.

[6]  A. Mantovani,et al.  Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade , 2020, Immunity.

[7]  Ron Yan,et al.  Immune Effects of γδ T Cells in Colorectal Cancer: A Review , 2020, Frontiers in Immunology.

[8]  Seiichiro Yamamoto,et al.  Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy , 2020, Oncology.

[9]  J. Galon,et al.  A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy , 2020, Clinical Cancer Research.

[10]  L. Pantanowitz,et al.  Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma , 2020, Modern Pathology.

[11]  Ruoxu Dou,et al.  Density and distribution of lymphocytes in pretherapeutic rectal cancer and response to neoadjuvant therapy , 2020, Gastroenterology report.

[12]  J. Galon,et al.  Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer , 2020, Journal for immunotherapy of cancer.

[13]  A. Abbas,et al.  Tumor Microenvironment Mediators CD8+- and FOXP3+-Labeled T Lymphocytes Are Prospective Prognosticators in Curatively Treated Rectal Cancer Patients , 2020, Journal of Gastrointestinal Cancer.

[14]  J. Galon,et al.  Immunoscore and its introduction in clinical practice. , 2020, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[15]  H. Ueno,et al.  Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer , 2020, BJS open.

[16]  T. Zheng,et al.  STING: a master regulator in the cancer-immunity cycle , 2019, Molecular Cancer.

[17]  S. Mori,et al.  Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer , 2019, The British journal of surgery.

[18]  Kebin Liu,et al.  Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes , 2019, Journal of Immunotherapy for Cancer.

[19]  Y. Huang,et al.  Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer , 2019, Bioscience reports.

[20]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[21]  J. Lee,et al.  A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients , 2018, Breast Cancer Research and Treatment.

[22]  P. Sehgal,et al.  Interferon-α-induced cytoplasmic MxA structures in hepatoma Huh7 and primary endothelial cells , 2018, Contemporary oncology.

[23]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[24]  P. Golstein,et al.  An early history of T cell-mediated cytotoxicity , 2018, Nature Reviews Immunology.

[25]  D. Aust,et al.  Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer , 2018, Oncoimmunology.

[26]  R. Langer,et al.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy , 2018, Virchows Archiv.

[27]  N. Baxter,et al.  A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. , 2017, The lancet. Gastroenterology & hepatology.

[28]  Tracey F Lee-Pullen,et al.  Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response , 2017, Oncotarget.

[29]  F. Qiu,et al.  Tumor-infiltrating CD39+ γδTregs are novel immunosuppressive T cells in human colorectal cancer , 2017, Oncoimmunology.

[30]  T. Gajewski,et al.  The host STING pathway at the interface of cancer and immunity. , 2016, The Journal of clinical investigation.

[31]  Xiao-yan Liu,et al.  Analysis of tumor-infiltrating gamma delta T cells in rectal cancer. , 2016, World journal of gastroenterology.

[32]  P. Staeheli,et al.  Leukocyte-Derived IFN-α/β and Epithelial IFN-λ Constitute a Compartmentalized Mucosal Defense System that Restricts Enteric Virus Infections , 2015, PLoS pathogens.

[33]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[34]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[35]  H. Nagawa,et al.  Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer , 2011, Radiation oncology.

[36]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Kochs,et al.  Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[38]  J. Casanova,et al.  Induction of MxA Gene Expression by Influenza A Virus Requires Type I or Type III Interferon Signaling , 2007, Journal of Virology.

[39]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[40]  R. Wilkinson,et al.  Plasmacytoid dendritic cells infiltrate the skin in positive tuberculin skin test indurations. , 2012, The Journal of investigative dermatology.

[41]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.